Annovis Bio, Inc.
ANVSHealthcare|Biotechnology|US
$0.84
+0.18 (+26.31%)
DCF Value
$0.84
Cash / Share
$0.50
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07284784 A Study of Buntanetap in Participants With PD | Parkinson's Disease (PD), Deep Brain Stimulation | P2P3 | Recruiting | 500 | Open-label | buntanetap/posiphen |
| NCT06709014 A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Early Alzheimers Disease | P3 | Active | 760 | RCT, Double-blind | buntanetap/posiphen, Placebo |
| NCT05357989 A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD | Parkinson's Disease, Idiopathic | P3 | Completed | 523 | RCT, Double-blind | buntanetap/posiphen, Placebo |
| NCT07757204 An Open-label Long-term Safety Study of Buntanetap in Participants With AD | Alzheimer's Dementia (AD) | P2P3 | Not Yet Recruiting | 400 | Open-label | buntanetap/posiphen |
| NCT05686044 A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD | Alzheimer Disease | P2P3 | Completed | 351 | RCT, Double-blind | Buntanetap/Posiphen, Placebo |
| NCT02925650 Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease | Alzheimer's Disease | P1P2 | Completed | 18 | RCT, Double-blind | Posiphen, Placebo |
| NCT04524351 Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients | Alzheimer Disease, Parkinson Disease | P1P2 | Completed | 75 | RCT, Double-blind | Posiphen, Placebo |
| NCT01072812 Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment | Alzheimer's Disease, Amnestic Mild Cognitive Impairment | P1 | Terminated | 5 | Open-label | Posiphen® tartrate capsules |